{"id":"NCT03580369","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","officialTitle":"A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Safety and Efficacy of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-17","primaryCompletion":"2021-07-16","completion":"2022-06-14","firstPosted":"2018-07-09","resultsPosted":"2022-12-30","lastUpdate":"2023-07-24"},"enrollment":1072,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Urticaria"],"interventions":[{"type":"BIOLOGICAL","name":"Ligelizumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Omalizumab","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ligelizumab 120 mg","type":"EXPERIMENTAL"},{"label":"Ligelizumab 72 mg","type":"EXPERIMENTAL"},{"label":"Omalizumab 300 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to establish safety and efficacy of ligelizumab in adolescent and adult subjects with Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab and over placebo.\n\nThe study population consisted of 1,072 male and female subjects aged ≥ 12 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-antihistamines.\n\nThis was a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There was a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.","primaryOutcome":{"measure":"Mean Change From Baseline in UAS7 at Week 12 (Multiple Imputation) of Adult Subjects","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Ligelizumab 72 mg","deltaMin":-19.368,"sd":0.668},{"arm":"Ligelizumab 120 mg","deltaMin":-19.33,"sd":0.66},{"arm":"Omalizumab 300 mg","deltaMin":-20.04,"sd":0.663},{"arm":"Placebo","deltaMin":-11.366,"sd":1.129}],"pValues":[{"comp":"OG000 vs OG003","p":"<.0001"},{"comp":"OG000 vs OG002","p":"0.7628"},{"comp":"OG001 vs OG003","p":"<.0001"},{"comp":"OG001 vs OG002","p":"0.7768"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":7},"locations":{"siteCount":161,"countries":["United States","Argentina","Austria","Brazil","Bulgaria","Canada","Colombia","Croatia","Czechia","Denmark","France","Germany","Greece","Guatemala","Hungary","India","Malaysia","Oman","Peru","Poland","Puerto Rico","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Thailand","Turkey (Türkiye)"]},"refs":{"pmids":["38008109"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1511"]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":316},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Arthralgia","Urticaria"]}}